High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Nicholas Turner, Andrew Tutt, Alan Ashworth, Hallmarks of 'BRCAness' in sporadic cancers Nature Reviews Cancer. ,vol. 4, pp. 814- 819 ,(2004) , 10.1038/NRC1457

Jos Jonkers, Ralph Meuwissen, Hanneke van der Gulden, Hans Peterse, Martin van der Valk, Anton Berns, Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genetics. ,vol. 29, pp. 418- 425 ,(2001) , 10.1038/NG747

M Raymond, E Rose, D E Housman, P Gros, Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistant cells. Molecular and Cellular Biology. ,vol. 10, pp. 1642- 1651 ,(1990) , 10.1128/MCB.10.4.1642

Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew N. J. Tutt, Damian A. Johnson, Tobias B. Richardson, Manuela Santarosa, Krystyna J. Dillon, Ian Hickson, Charlotte Knights, Niall M. B. Martin, Stephen P. Jackson, Graeme C. M. Smith, Alan Ashworth, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature. ,vol. 434, pp. 917- 921 ,(2005) , 10.1038/NATURE03445

S ROTTENBERG, J JONKERS, Modeling therapy resistance in genetically engineered mouse cancer models Drug Resistance Updates. ,vol. 11, pp. 51- 60 ,(2008) , 10.1016/J.DRUP.2007.11.002

Thomas Helleday, Eva Petermann, Cecilia Lundin, Ben Hodgson, Ricky A. Sharma, DNA repair pathways as targets for cancer therapy Nature Reviews Cancer. ,vol. 8, pp. 193- 204 ,(2008) , 10.1038/NRC2342

S. Rottenberg, A. O. H. Nygren, M. Pajic, F. W. B. van Leeuwen, I. van der Heijden, K. van de Wetering, X. Liu, K. E. de Visser, K. G. Gilhuijs, O. van Tellingen, J. P. Schouten, J. Jonkers, P. Borst, Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer Proceedings of the National Academy of Sciences of the United States of America. ,vol. 104, pp. 12117- 12122 ,(2007) , 10.1073/PNAS.0702955104

Norman E. Sharpless, Ronald A. DePinho, The mighty mouse: genetically engineered mouse models in cancer drug development Nature Reviews Drug Discovery. ,vol. 5, pp. 741- 754 ,(2006) , 10.1038/NRD2110

Helen E. Bryant, Niklas Schultz, Huw D. Thomas, Kayan M. Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J. Curtin, Thomas Helleday, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature. ,vol. 434, pp. 913- 917 ,(2005) , 10.1038/NATURE03443

Keith A Menear, Claire Adcock, Robert Boulter, Xiao-ling Cockcroft, Louise Copsey, Aaron Cranston, Krystyna J Dillon, Jan Drzewiecki, Sheila Garman, Sylvie Gomez, Hashim Javaid, Frank Kerrigan, Charlotte Knights, Alan Lau, Vincent M Loh Jr, Ian TW Matthews, Stephen Moore, Mark J O’Connor, Graeme CM Smith, Niall MB Martin, None, 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. Journal of Medicinal Chemistry. ,vol. 51, pp. 6581- 6591 ,(2008) , 10.1021/JM8001263